Immunology and inflammation

News

Lawsuit claims J&J illegally delayed Stelara biosimilars

A lawsuit in the US is accusing Johnson & Johnson of unlawfully delaying the onset of biosimilar competition to its immunology blockbuster Stelara beyond its US patent

News

Aclaris slashes staff as it trims its pipeline

Aclaris Therapeutics has said it will cut 46% of its workforce after deciding to discontinue the development of lead drug zunsemetinib (ATI-450) for immuno-inflammatory in

News

InDex craters on phase 3 ulcerative colitis failure

InDex Pharmaceuticals has said it will abandon a phase 3 trial of its lead drug cobitolimod in moderate-to-severe ulcerative colitis, its only clinical-stage programme, wr

News

Rumour confirmed as Roche buys Telavant for $7.1bn

Roche has announced a $7.1 billion deal to acquire Roivant group company Telavant and its RVT-301 drug candidate for inflammatory bowel disease (IBD), confirming rumours t

News

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used S

News

MSD gives warning to UK ahead of $1.3bn facility work

In 2017, MSD made the decision to open a $1.32 billion, 220,000 sq ft research facility in the heart of London’s ‘knowledge quarter’ around King’s Cross.

Lawsuit claims J&J illegally delayed Stelara biosimilars

Aclaris slashes staff as it trims its pipeline

InDex craters on phase 3 ulcerative colitis failure

Rumour confirmed as Roche buys Telavant for $7.1bn

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

MSD gives warning to UK ahead of $1.3bn facility work

BMS's Breyanzi is first CAR-T for marginal zone lymphoma

How to meet your physicians where they are online

Immunology and inflammation

Editor's Picks